Samsung Biologics

Últimas noticias

Titulares en el idioma original de la fuente.

• 
  삼성바이오로직스 3차 조정도 결렬…노조 “단체행동 가능성” 거론 : 네이버 블로그 (se abre en una pestaña nueva)

  Naver Blog · 3 oct 2026

• 삼성바이오로직스, 국내외 제약바이오 4개 행사 참여 (se abre en una pestaña nueva)

  바이오스펙테이터 · 1 oct 2026

• Samsung Biologics Labor Talks Break Down Again, Union Signals Possible Collective Action (se abre en una pestaña nueva)

  알파경제 · 1 oct 2026

• ₩1,550,655 저항선에서 돌파를 시도하는 Samsung Biologics 주식: 주목할 상승 목표 (se abre en una pestaña nueva)

  Traders Union · 1 oct 2026

• Samsung Biologics Redefines Biopharmaceuticals: 3.5-Month Development Time Reduction Revealed at BPI 2026 (se abre en una pestaña nueva)

  뉴스1 · 29 sept 2026

• 
  Samsung Biologics publishes prospectus for PolyPeptide public tender offer (se abre en una pestaña nueva)

  PR Newswire · 31 ago 2026

• 
  Samsung Biologics Announces KRW 3 Trillion Rights Offering to Fund Its Next-Phase Expansion (se abre en una pestaña nueva)

  PR Newswire · 27 ago 2026

• 
  Samsung Biologics Reports Second Quarter 2026 Financial Results (se abre en una pestaña nueva)

  PR Newswire · 22 jul 2026

• 
  Samsung Biologics: geographic diversification is a sound business decision (se abre en una pestaña nueva)

  Pharmaceutical Technology · 22 jul 2026

• 
  Samsung Biologics to acquire PolyPeptide in $1.81bn cash deal (se abre en una pestaña nueva)

  Pharmaceutical Technology · 20 jul 2026

• 
  Bristol Myers to build ‘powerful’ AI factory; Samsung Biologics bids for peptide maker (se abre en una pestaña nueva)

  BioPharma Dive · 20 jul 2026

• 
  Samsung Biologics announces all-cash offer to acquire PolyPeptide, accelerating multi-modality strategy and expanding global network across U.S., Europe, and India (se abre en una pestaña nueva)

  PR Newswire · 19 jul 2026

• South Korea Centrifugation Market: Focus on Product, Model Type, Application, and End User - Analysis and Forecast, 2025-2035 Published; Maps Biopharm Manufacturing Demand (se abre en una pestaña nueva)

  9 jul 2026

• 
  Samsung Biologics Releases 2026 ESG Report, Highlighting Progress in Sustainable Operations and Responsible Growth (se abre en una pestaña nueva)

  PR Newswire · 30 jun 2026

• Pharma’s manufacturing reconfigurations provide CDMOs with expansion opportunities (se abre en una pestaña nueva)

  12 may 2026

• 
  Samsung Biologics Listed on Dow Jones Best-in-Class World Index for Fifth Consecutive Year (se abre en una pestaña nueva)

  PR Newswire · 5 may 2026

• 
  Samsung Biologics Reports First Quarter 2026 Financial Results (se abre en una pestaña nueva)

  PR Newswire · 22 abr 2026

• 
  Samsung Biologics acquires GSK’s facility in Maryland, US (se abre en una pestaña nueva)

  Investment Monitor · 1 abr 2026

• 
  Samsung Biologics completes acquisition of GSK's manufacturing facility in Rockville, Maryland (se abre en una pestaña nueva)

  PR Newswire · 31 mar 2026